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The mechanism of action of isoniazid (INH), a first-line antituberculosis drug, is complex, as mutations in
at least five different genes (katG, inhA, ahpC, kasA, and ndh) have been found to correlate with isoniazid
resistance. Despite this complexity, a preponderance of evidence implicates inhA, which codes for an enoyl-acyl
carrier protein reductase of the fatty acid synthase II (FASII), as the primary target of INH. However, INH
treatment of Mycobacterium tuberculosis causes the accumulation of hexacosanoic acid (C26:0), a result unex-
pected for the blocking of an enoyl-reductase. To test whether inactivation of InhA is identical to INH treatment
of mycobacteria, we isolated a temperature-sensitive mutation in the inhA gene of Mycobacterium smegmatis that
rendered InhA inactive at 42°C. Thermal inactivation of InhA in M. smegmatis resulted in the inhibition of
mycolic acid biosynthesis, a decrease in hexadecanoic acid (C16:0) and a concomitant increase of tetracosanoic
acid (C24:0) in a manner equivalent to that seen in INH-treated cells. Similarly, INH treatment of Mycobac-
terium bovis BCG caused an inhibition of mycolic acid biosynthesis, a decrease in C16:0, and a concomitant
accumulation of C26:0. Moreover, the InhA-inactivated cells, like INH-treated cells, underwent a drastic
morphological change, leading to cell lysis. These data show that InhA inactivation, alone, is sufficient to
induce the accumulation of saturated fatty acids, cell wall alterations, and cell lysis and are consistent with
InhA being a primary target of INH.
Isoniazid (INH) remains one of the key drugs in global
control strategies to treat tuberculosis, despite the increasing
numbers of primary and secondary resistance (8). INH was first
discovered to have antituberculosis activity in 1952 in random
screens, though its target of action was unknown (5, 11). Early
studies had shown that INH inhibited the synthesis of mycolic
acids, a-alkyl b-hydroxy long-chain fatty acids (60 to 90 car-
bons in length) that cover the surface of mycobacteria (34, 40).
Using lipid fractionation methodologies, Takayama and col-
leagues later demonstrated that INH treatment of Mycobacte-
rium tuberculosis inhibited mycolic acid biosynthesis and
caused the accumulation of hexacosanoic acid (C26:0), a satu-
rated C26 fatty acid (36). They proposed three possible sites of
action: (i) a desaturase, (ii) a cyclopropanase, and (iii) an
enzyme involved in long-chain fatty acid elongation.
Using newly developed gene transfer systems for mycobac-
teria, we identified a novel gene, inhA, as a target for INH (1).
Further work revealed that InhA encoded an NADH-specific
enoyl-acyl carrier protein (ACP) reductase activity (10, 29)
which converts D2-unsaturated to saturated fatty acids and is
involved in the elongation of long-chain fatty acids to mycolic
acids. This enzymatic activity led Mdluli et al. to argue that
InhA was not the primary target of INH for M. tuberculosis (22,
23). Their major objection was that a block in an enoyl-ACP
reductase should lead to the accumulation of monounsatu-
rated intermediates and could not account for the accumula-
tion of C26:0 observed following INH treatment of M. tubercu-
losis.
Unlike most organisms, mycobacteria have two fatty acid
synthases, the fatty acid synthase I (FASI) and FASII systems
(Fig. 1A). The discovery that mycobacteria had FASI was sur-
prising, as it is the first prokaryote shown to have FASI, a
multidomain enzyme that encodes all the activities necessary
for fatty acid synthesis in one large polypeptide (7). The FASI
system from Mycobacterium smegmatis produces saturated
fatty acids in a bimodal pattern of palmitate (C16:0) and tetra-
cosanoate (C24:0) (6, 27). In contrast, the ACP-requiring FASII
system contains a series of independent enzymes, including
InhA (21), and is responsible for the biosynthesis of mycolic
acid by elongation of the FASI products.
In this report, we sought to isolate mutants of M. smegmatis
that would map to inhA and confer thermosensitivity. Using
such an inhA(Ts) allele, it would be possible to test if thermal
inactivation of InhA induces the same events leading to the
death of M. smegmatis as INH treatment. Two independent
mutants were identified that had an identical single point mu-
tation within inhA. The analogous mutation was engineered
into the M. tuberculosis inhA gene, and the expressed protein
was demonstrated to be inactive at the nonpermissive temper-
ature. Thermal inactivation of the two M. smegmatis strains
harboring the inhA(Ts) allele resulted in mycolic acid biosyn-
thesis inhibition and accumulation of long-chain saturated
fatty acids, with no detectable amount of D2-unsaturated fatty
acids. Similar fatty acid profiles were observed following INH
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treatment of M. smegmatis or Mycobacterium bovis BCG. Fur-
thermore, both InhA thermal inactivation and INH treatment
caused similar morphological changes to the cell wall, leading
to cell lysis. In the context of these results, we present a model
in which InhA is the primary target of INH in M. tuberculosis,
M. bovis BCG, and M. smegmatis.
MATERIALS AND METHODS
Bacterial strains. The mycobacterial strains used in this study are described in
Table 1. The M. smegmatis mutants were obtained from the laboratory wild-type
(wt) strain mc2155 (33).
Isolation of spontaneous INH-R mutants. Spontaneous INH-resistant
(INH-R) mutants were isolated from one nonmutagenized culture of mc22354, a
merodiploid for the ndh gene of M. smegmatis, and grown in Middlebrook 7H9
broth (Difco) supplemented with 0.2% glycerol, 10% ADS enrichment, and 0.5%
Tween 80. The culture was incubated while shaking for 5 days at 30°C. Tenfold
serial dilutions were plated on minimal (Middlebrook 7H9 supplemented with
0.2% glycerol, 10% ADS, and 1.5% agar) and rich (Mueller-Hinton agar [Difco])
agar plates containing INH (25 mg/ml). The plates were incubated at 30°C for 6
days.
Revertant analysis. The thermosensitive strains were grown at 30°C to an
optical density (OD) of 1.5 to 2.0. Tenfold serial dilutions were plated on rich
and minimal media. The plates were incubated at 30°C (for titration of the
cultures) and 42°C for 5 days. The frequency of reversion was determined by the
number of CFU at 42°C divided by the titer.
Transformation experiments. Cultures were grown at 30°C (OD of 1.0), spun
down, washed twice with cold 10% glycerol, and resuspended in 10% glycerol
(0.5 ml). To the cold cell suspension (100 ml) was added pYUB1019 (a 3-kb
fragment containing orf1-inhA-orf3 subcloned into pMD31, a kanamycin-resis-
tant [Kanr] Escherichia coli mycobacterial shuttle plasmid; 1 ml). The cold sus-
pension was electroporated (2.5 V, 25 mFd, 1,000 V), plated on kanamycin (20
mg/ml)-containing plates, and incubated at 30°C for 7 days.
Transduction experiments. Cultures were grown in 20 ml of minimal medium
containing INH (25 mg/ml) at 30°C (OD of 1.0), spun down, and resuspended in
2 ml of SM buffer (0.1 M NaCl, 8 mM MgSO4 z 7H2O, 50 mM Tris hydrochloride,
pH 7.5) containing 0.5% Tween 80 and 10 mM CaCl2. The cell suspension (200
ml) was mixed with 200-ml aliquots of high-titer I3 transducing lysate dilutions
(108 and 109 phage-forming units/ml) and incubated without shaking at 30°C for
30 min. After addition of Luria-Bertani broth (Difco) (400 ml), the cell suspen-
sion was incubated with shaking at 30°C for 90 min and plated on Luria-Bertani
medium containing 10 mM sodium citrate, and the plates were incubated at 30°C
for 6 days. Isolated transductants were freed of phage by streaking on Luria-
Bertani medium containing 10 mM sodium citrate.
PCR amplification. The inhA gene was amplified from chromosomal DNA,
using the primers TW175 (59-CCAAATGACAGGACTACTCG-39) and TW176
(59-TCACAACAGATGCGTGCTGG-39) along with amplification of this gene
from the wt mc2155 chromosome. These products were directly sequenced bidi-
rectionally and aligned against each other.
Construction of a V238F mutant M. tuberculosis InhA protein and enzymatic
characterization. The V238F mutation was introduced into the pET M. tuber-
culosis inhA expression vector (10) using an inverse PCR methodology (2) and
verified by DNA sequence analysis. The InhA protein was purified as previously
FIG. 1. Fatty acid biosynthesis in mycobacteria (A) and activation of INH (B). (A) Fatty acid synthetase I carries on the synthesis of C16:0 and C24:0. One or both
fatty acid products act as substrates for the synthesis of mycolic acids by fatty acid synthetase II. Putative targets for the action of activated INH are underlined. (B)
INH is activated by the action of a catalase-peroxidase encoded by the katG gene. Shown are two possible products of this reaction, involved in the formation of the
INH-NAD adduct (31).
TABLE 1. Bacterial strains used in this study
M. smegmatis strain Genotype Source or reference
mc2155 ept-1 33
mc2651 ept-1 inhA1 1
mc2699 ept-1 inhA linked to aph 1
mc22354 ept-1 attB::pYUB412::ndh 25
mc22359 ept-1 attB::pYUB412::ndh inhA40 INH-R, Ts mutant of mc22354
mc22360 ept-1 attB::pYUB412::ndh inhA41 INH-R, Ts mutant of mc22354
mc22361 ept-1 attB::pYUB412::ndh inhA1 aph I3 (mc2699) 3 mc22359
mc22362 ept-1 attB::pYUB412::ndh inhA1 aph I3 (mc2699) 3 mc22360
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described (29). All enzyme assays were done in 30 mM piperazine-N,N9-bis(2-
ethanesulfonic) acid (PIPES buffer), pH 6.8, using 2-trans-octenoyl-coenzyme A
(CoA) (0.6 mM) as a substrate. The extinction coefficients of NADH at 340 and
380 nm were 6,220 and 1,128 M21 cm21, respectively. The enzyme activity was
defined by the number of micromoles of NADH turned over per minute per
milligram of protein. Enzyme activities of the InhA(Ts) (V238F) mutant were
measured at various temperatures and compared with those of wt InhA. Small
aliquots of enzyme solution were injected to assay solution in a quartz cell. After
mixing vigorously, a decrease of absorbency at 380 nm for the Ts mutant and 340
nm for the wt enzyme was recorded for 5 min at 20, 37, and 42°C. Final
concentrations of InhA and NADH were 1.08 mM (per active site) and 800 mM
for the Ts mutant and 0.034 mM (per active site) and 5 mM for wt InhA,
respectively. In this experiment, NADH concentrations were set around Km
values for NADH because enzyme activity was significantly inhibited at higher
NADH concentration (.1 mM) for the Ts mutant as described below. Enzyme
activity was measured at various NADH concentrations from 0.1 to 1.6 mM at
20°C. The decrease of absorbance was recorded at 380 nm. Kinetic parameters,
Km and Vmax, were calculated from initial rates at each NADH concentrations by
using KaleidaGraph software (Synergy Software Inc.).
Time course assays. Time course assays were determined spectrophotometri-
cally by monitoring NADH oxidation at 340 nm using a Shimadzu UV-1201
spectrophotometer with a time course program pack. Shimadzu PC 1201 per-
sonal spectroscopy software was used to automate the monitoring of the reac-
tions. All reactions were run in 30 mM PIPES buffer, pH 6.8. Reactions were
conducted at fixed concentrations of NADH (180 mM) and 2-trans-dodecenoyl-
CoA (50 mM). Cell lysate from mc22359 was diluted, substrates were added, and
the spectrophotometer was zeroed upon addition of NADH. Reactions were
monitored for 5 min at 0.5-s intervals and were conducted at 25, 37, and 42°C.
Radiolabeling of lipids with [1-14C]acetate. Cultures from M. smegmatis or
BCG were grown in Middlebrook 7H9 broth supplemented with 0.2% glycerol,
10% ADS enrichment, and Tween 80 (0.5% for M. smegmatis and 0.1% for BCG
Pasteur) to an OD at 600 nm of ;0.8 and then incubated at 42°C for 1 h with or
without INH (25 mg/ml for M. smegmatis and 1 mg/ml for BCG). [1-14C]Acetate
(0.3 mCi/ml) was added, and the incubation was continued for another hour.
Cells were collected by centrifugation and lyophilized.
Analysis of fatty acids by TLC. Fatty acid methyl esters (FAMEs) and mycolic
acid methyl esters (MAMEs) were obtained by alkaline treatment of the pellet,
esterification with methyl iodide, and extraction with dichloromethane. After
concentration to dryness, the residue was resuspended in diethyl ether. Radio-
labeled fatty acid extracts were spotted (10 ml of lipid extract; ;20,000 cpm) by
silica gel thin-layer chromatography (TLC) and eluted (double elution with
hexane-ethyl acetate [9:1, vol/vol]). Detection of radiolabeled species was done
by autoradiography. The autoradiograms were obtained after exposure at 280°C
for 2 days on X-ray film.
Analysis of fatty acids by HPLC. Samples were prepared by saponification of
the cell pellets, acidification, extraction with chloroform, evaporation, and der-
ivatization to their UV-absorbing p-bromophenacyl esters using the p-bromo-
phenacyl ester kit (part no. 18036) from Alltech Associates, Inc. High-perfor-
mance liquid chromatography (HPLC) analysis of the p-bromophenacyl fatty
acid esters was conducted on a Hewlett-Packard model HP1100 gradient chro-
matograph equipped with an HP1100 series thermostated column compartment,
an HP1100 series diode array detector, and an IN/US b-RAM model 2B
flowthrough radioisotope beta-gamma radiation detector. The data were col-
lected and processed with HP Chemstation software (version A.04.01). Separa-
tion of the p-bromophenacyl fatty acid esters was achieved using an Alltech
all-guard column (part no. 77082 and 96080) coupled to a reverse-phase C18
column (4.6 by 150 mm; 3-mm column diameter; Alltima C18 [Alltech]). The
column temperature was set at 45°C, the flow rate was set at 2 ml/min, the sample
injection volume was set at 95 ml, and the wavelength was set at 260 nm. The
mobile phase was acetonitrile-water employed as an isocratic elution (83:17,
vol/vol) for 20 min (24), followed by a linear increase to 100% acetonitrile in 2
min and held at 100% acetonitrile for 18 min. The 14C-labeled fatty acid esters
were detected using In-FlowTM ES (IN/US Systems, Inc., Tampa, Fla.) at a 3:1
(vol/vol) ratio with the column eluant. The chromatograms’ peaks were identified
by comparison with chromatograms of p-bromophenacyl fatty acid ester stan-
dards. Saturated fatty acid standards were purchased from Sigma. 2-Alkenoic
acid standards were obtained as described below.
Synthesis of 2-trans-alkenoic acids. Oxidation of the n-alcohols (C14 to C22)
with pyridinium chlorochromate in dichloromethane for 4 h at room temperature
gave the corresponding aldehydes in 90 to 97% yield (9). The Wittig reaction of
the aldehydes with ethyl (triphenylphosphoranylidene)acetate in dry acetonitrile
for 72 h at room temperature afforded ethyl 2-trans-alkenoates in 50 to 80% yield
(26). The esters were saponified with a 10% methanolic solution of potassium
hydroxide for 2 h at reflux. The resulting 2-trans-alkenoic acids were purified by
flash chromatography and recrystallized in hexane (80 to 90%). The structures of
the final products and intermediates were confirmed by proton and carbon
nuclear magnetic resonance spectroscopy.
Scanning electron microscopy (SEM). Strains were grown in Mueller-Hinton
or 7H9 broth at 30°C to an OD of ;0.2, INH (25 mg/ml) was added to the M.
smegmatis mc2155 culture, and then the cultures were shifted to 42°C. Samples
(50 to 100 ml) were taken at 0, 3, 6, and 9 h after the temperature shift. The
samples were fixed in 2.5% glutaraldehyde in 0.1 M sodium cacodylate, pH 7.4,
plated out on poly-L-lysine-coated coverslips, dehydrated through a graded series
of ethanol, critical point dried using liquid carbon dioxide in a Tousimis Samdri
(Rockville, Md.) 790 critical point drier, and then sputter coated with gold-
palladium in a Denton (Cherry Hill, N.J.) vacuum desk-1 sputter coater. The
samples were examined in a JEOL (Peabody, Mass.) JSM6400 scanning electron
microscope using an accelerating voltage of 15 kV.
RESULTS
Isolation of a Ts allele of inhA in M. smegmatis. A Ts allele
of inhA, the inhA(Ts) allele, was identified by screening a large
set of spontaneous INH-R mutants of M. smegmatis using a
strain of M. smegmatis containing a second copy of ndh. This
strategy was based on our previous work in which INH-R and
Ts mutants were isolated, but surprisingly, their mutations
mapped to ndh, the gene encoding an NADH dehydrogenase
(25). These mutations had pleiotropic phenotypes including
coresistance to INH and ethionamide (ETH), temperature
sensitivity for growth, and auxotrophies as a result of increased
NADH/NAD ratios in the cell (25). We hypothesized that
INH-R, Ts mutations in inhA would be present in a population
of spontaneous mutants, but much less frequent than muta-
tions in ndh. Therefore, mutations in inhA could be enriched
by using a strain that was a merodiploid for ndh and by plating
on minimal medium with INH, which would select against the
auxotrophic phenotype associated with many ndh mutants.
The M. smegmatis ndh gene was introduced into mc2155 at
the chromosomal attB site for the mycobacterial phage L5
using an integration-proficient vector to make mc22354. Spon-
taneous INH-R mutants were isolated from a nonmutagenized
culture of mc22354 at a frequency of 4 3 1027 on 7H9 minimal
agar medium and 4 3 1026 on a rich Mueller-Hinton agar
medium. The majority of colonies from both the rich (47 of 52)
and the minimal (50 of 52) media were coresistant to both INH
and ETH, with a higher frequency of Ts phenotypes found
from INH-R mutants isolated on the minimal medium (11 of
52) compared to the rich medium (3 of 53). Three of the
mutants failed to generate cultures in liquid media and were
not analyzed further. Eleven of the remaining mutants were
INH-R, ETH-R, and Ts and were subjected to further analysis.
Each of the 11 INH-R, ETH-R, and Ts mutants was trans-
formed with the M. smegmatis inhA gene on multicopy plasmid.
Two of the 11 mutants, one isolated from the minimal medium,
mc22359, and one isolated from the complex medium,
mc22360, were able to grow at 42°C when transformed with the
multicopy inhA. To further test if the mutations conferring all
three phenotypes mapped to inhA, an allelic exchange I3 trans-
ductional analysis was performed using a donor strain, mc2699,
which had the wild-type inhA allele closely linked to an aph
gene of a mini-Tn5 (1). The frequency of transduction of Kanr
was between 1027 and 1028 per mc22359 or mc22360 input cell
in five different experiments (Table 2). The majority of the
TABLE 2. I3 transductional analysis with inhA linked to aph in
mc22359 and mc22360
Cross and expt no. INH-S, Tr
a colonies/
Kanr colonies (%)
I3 (mc2699) 3 mc22359 [inhA(Ts)]
1........................................................................................12/18 (66)
2........................................................................................46/50 (92)
I3 (mc2699) 3 mc22360 [inhA(Ts)]
1........................................................................................15/15 (100)
2........................................................................................47/50 (94)
3........................................................................................ 7/8 (88)
a Tr, temperature resistant.
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Kanr transductants (66 to 100%) had acquired the ability to
grow at 42°C, demonstrating a tight linkage of the Kanr marker
with inhA that was previously reported (1). Moreover, 100% of
the transductants that acquired the ability to grow at 42°C were
sensitive to both INH and ETH. The cosegregation of the
three phenotypes strongly suggests that a mutation within the
inhA gene was responsible for all three phenotypes.
Both inhA(Ts) mutants showed high resistance to INH (the
MIC was greater than 100 mg/ml, determined by plating onto
medium containing different concentrations of INH [25] [data
not shown]). Sequence analysis revealed a single point muta-
tion, a G-to-T conversion (G712T), that caused a Val-to-Phe
amino acid substitution (V238F) in InhA in both mc22359 and
mc22360. Notably, the amino acid sequence of the InhA pro-
tein was found to be highly homologous to the amino acid
sequence of the fabI-encoded enoyl-ACP reductase from E.
coli and that similar substitution (Ser-to-Phe amino acid
change) at a comparable position (position 241) in FabI from
E. coli and Salmonella enterica serovar Typhimurium caused a
Ts phenotype in these organisms (4). This V238F mutation
encodes an amino acid substitution that is located in the
NADH binding site of the InhA protein. All previously defined
mutations that cause an alteration in the NADH binding site of
InhA have been found to correlate with INH-R and ETH-R (1,
2). If the G712T mutation is solely responsible for the INH-R,
ETH-R, and, Ts phenotypes, then the Kanr transductants
found to have regained the wt phenotypes as described above
should have regained the G at position 712 in the inhA gene,
regenerating the wt inhA sequence. This change could be
readily detected, as the G712T mutation alters a PshAI restric-
tion site (59 . . . GACNNNNGTC . . . 39 [mutation under-
lined]) within the inhA gene. Three independent transductants
of mc22359 and mc22360 were analyzed by PCR amplification
of a segment of inhA and digestion with PshAI. All transduc-
tants regained the PshAI site like the mc22354 parent, while
both Ts mutants were left uncut by PshAI. Thus, all transduc-
tants that regained the three parental phenotypes—(i) ability
to grow at 42°C, (ii) INH-S, and (iii) ETH-S—regained the wt
DNA sequence at position 712. This result is consistent with
the premise that the G712T mutation in inhA is solely respon-
sible for the INH-R, ETH-R, and Ts phenotypes.
To further confirm that this mutation within inhA was re-
sponsible for temperature sensitivity and antibiotic resistance,
we sought revertants that map to the inhA gene. Revertants
could be consistently obtained by plating cells for growth at
42°C, but all at very low frequencies of less than 1028. All 19
revertants analyzed acquired single point mutations within the
mutated inhA gene (Table 3). The majority of mutants had
acquired mutations that caused amino acid substitutions at
amino acid 238. One class became INH-S (F238V, F238L, and
F238C), and another remained INH-R (F238I). One addi-
tional class of revertants encodes an intramolecular suppressor
mutation causing a glycine-to-cysteine amino acid substitution
at amino acid 102. While this suppressing mutation allowed the
revertants to grow at 42°C, both of these revertants retained
their INH-R and ETH-R phenotypes.
The revertants having a F238V or F238L amino acid change
had the same growth rate at 42°C as the wt mc2155 or the
parental strain mc22354, while other revertants (F238C, F238I,
and G102C) had a growth defect as shown by a longer doubling
time (data not shown).
The V238F-altered InhA enoyl-ACP reductase loses activity
at 42°C. E. coli-expressed V238F M. tuberculosis InhA was
purified to homogeneity, and its ability to catalyze the reduc-
tion of 2-trans-octenoyl-CoA was tested at various tempera-
tures (Table 4). The V238F mutant showed activity similar to
the wt enzyme at the permissive temperature of 20°C under
saturating conditions of NADH (29). The Km and Vmax values
of the InhA(Ts) mutant were determined to be 0.88 6 0.15
mM and 1.22 6 0.12 U/mg of protein, respectively. The Km of
the InhA(Ts) is about 200 times larger than that of the wt
enzyme (4 mM), and the Vmax is less than one-half that of the
wt enzyme (ca. 3 U/mg protein). In addition, InhA(Ts) mutant
activity was significantly inhibited at higher NADH concentra-
tions (.1 mM). The V238F mutant M. tuberculosis InhA en-
zyme also showed a significant reduction in its catalytic activity
at 37°C and a complete inactivation at 42°C. Similar results
were obtained for the V238F mutant of M. smegmatis, with a
reduction of InhA activity at 37°C (by 33%) and a total loss of
InhA activity at 42°C.
TABLE 3. Sequence analysis of inhA alleles from temperature-resistant (Tr) revertants
Strain Phenotype DNA change(s) Amino acid change No. with phenotype/no.of mutants analyzed
Revertants of mc22359 [inhA(Ts)]
mc22363, mc22364 Tr INH-Sa 712TTA, 712TTG F238L 4/9
mc22365 Tr INH-S 712TGC F238C 1/9
mc22366 Tr INH-R 304TGT G102C 4/9
Revertants of mc22360 [inhA(Ts)]
mc22367 Tr INH-S 712GTC F238V 1/10
mc22368, mc22369, mc22370 Tr INH-S 712TTA, 712TTG, 712CTC F238L 4/10
mc22371 Tr INH-S 712TGC F238C 2/10
mc22372 Tr INH-R 712ATC F238I 1/10
mc22373 Tr INH-R 304TGT G102C 2/10
a INH-S, INH susceptible.
TABLE 4. Enzymatic activities of wt InhA and InhA(Ts) (V238F)
Temperature (°C)a
Enzymatic activity (U/mg of protein)
(% residual activityb) of:
wt InhA InhA(Ts) (V238F)
20 1.51 (100) 0.70 (100)
37 0.98 (65) 0.051 (7)
42 0.51 (34) NDc (0)
a Two experiments were done for each temperature.
b Numbers in parentheses are percentages of residual activity at each temper-
ature, assuming enzyme activity at 20°C to be 100%.
c ND, not detected.
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Thermal inactivation of InhA inhibits mycolic acid biosyn-
thesis and causes an accumulation of FASI end products.
Takayama and colleagues had shown that M. tuberculosis ac-
cumulates C26:0 following 1 h of INH treatment (36). We
hypothesize that the accumulated C26:0 is an end product gen-
erated by FASI following the inhibition of the FASII pathway
through inhibition of InhA. The in vitro activities of FASI from
M. smegmatis and M. bovis BCG were characterized by Bloch
(27) and Kikuchi et al. (16), respectively. A bimodal fatty acid
pattern of C16:0 and C24:0 was reported for the fast grower M.
smegmatis (27), while the slow grower BCG displayed a bi-
modal fatty acid pattern of C16:0 and C26:0 (16). To test our
hypothesis, we first examined INH treatment of BCG. One
hour of INH treatment inhibited the synthesis of mycolic acids
(MAMEs) and resulted in an accumulation of nonhydroxy-
lated fatty acids (FAMEs) by TLC (Fig. 2, lane 12). To identify
the fatty acids that accumulated following INH treatment, the
radiolabeled materials were analyzed by HPLC. The nonhy-
droxylated fatty acids, present in the radiolabeled samples,
were found to be saturated fatty acids with no detectable levels
of D2-unsaturated products (Fig. 3). These fatty acids had
chain lengths ranging from 16 to 26 carbons, similar to the fatty
acid pattern described for BCG FASI in vitro (16). There was
a dramatic shift in the INH-treated cells in the amounts of
C26:0 compared to C16:0 (Fig. 4). While the percentage of other
FASI intermediates, namely, C18:0, C20:0, C22:0, and C24:0, re-
mained mostly unchanged (22, 5, 5, and 12%, respectively), we
observed a 25% decrease in the level of C16:0 and a 36%
increase in the level of C26:0 when the cells were treated with
INH.
The same experiment was conducted with the fast-growing
M. smegmatis. The fatty acids produced by M. smegmatis during
INH treatment at 42°C also consisted of saturated fatty acids
with no detectable levels of D2-unsaturated products (Fig. 3).
The only notable difference between the INH treatment of
BCG and M. smegmatis was that the longest fatty acid isolated
was C24:0 for M. smegmatis and C26:0 for BCG. This is consis-
tent with the previous in vitro characterizations of FASI activ-
ities of M. smegmatis and BCG (16, 27). Following INH treat-
ment of M. smegmatis cells, the fatty acid distribution became
similar to that of BCG (Fig. 4). While the percentages of C18:0,
C20:0, and C22:0 remained constant (10, 5, and 9%, respective-
ly), we observed an 18% decrease in the level of C16:0 and up
FIG. 2. Autoradiographic TLC of 14C-labeled fatty acids of M. smegmatis
following INH treatment or InhA inactivation. In lanes 1 to 4, the labelings were
done at 30°C: lane 1, wt mc2155; lane 2, ndh merodiploid mc22354; lane 3,
mc22359; lane 4, mc22360. In lanes 5 to 12, the labelings were done at 42°C: lane
5, wt mc2155; lane 6, wt mc2155 plus INH (50 mg/ml); lane 7, mc22354; lane 8,
mc22354 plus INH (50 mg/ml); lane 9, mc22359; lane 10, mc22360; lane 11, M.
bovis BCG Pasteur plus INH (1 mg/ml); lane 12, M. bovis BCG Pasteur.
FIG. 3. HPLC analysis of 14C-labeled fatty acids from INH-treated or InhA-inactivated samples. The retention times for the p-bromophenacyl 2-alkanoyl esters
using the elution conditions described in Materials and Methods are as follows: C16:0, 18.6 min; C18:0, 23.9 min; C20:0, 25.5 min; C22:0, 27.5 min; C24:0, 30.2 min. The
retention times for p-bromophenacyl 2-alkenoyl esters are the following: D2-C16, 15.4 min; D2-C18, 23.0 min; D2-C20, 24.6 min; and D2-C24, 28.8 min.
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to 29% increase in the level of C24:0 when the cells were
treated with INH.
To test if FASI end products accumulate following InhA
inactivation, we performed the same analyses on the inhA(Ts)
mutants. Both mc22359 and mc22360 mutants have the same
fatty acid profile as the wt M. smegmatis and their parent
strain mc22354 at the permissive temperature (Fig. 2, lanes 1
to 4). Their fatty acid profiles were then examined following a
1-h incubation at 42°C. Analysis by TLC revealed that both
inhA(Ts) mutants failed to make mycolates and accumulated
nonhydroxylated fatty acids (Fig. 2, lanes 9 and 10), identical to
what was observed for INH-treated M. smegmatis cultures (Fig.
2, lanes 6 and 8). The accumulated products were analyzed
by HPLC, revealing the presence of saturated fatty acids with
no D2-unsaturated fatty acids (Fig. 3). As for INH-treated M.
smegmatis, we observed a 26% decrease in C16:0 and up to 50%
increase in C24:0 (Fig. 4), while the other intermediates stayed
unchanged. This analysis clearly establishes that a block in the
inhA-encoded enoyl-ACP reductase induces an accumulation
of a long-chain saturated fatty acid, comparable to INH treat-
ment of M. smegmatis cells, with no detectable levels of D2-
unsaturated products.
Lysis of M. smegmatis is induced by thermal inactivation of
InhA. Takayama and colleagues had previously demonstrated
that the viability of M. tuberculosis cells was unaffected after
the first hour of INH treatment and gradually declined to 18%
viability after 3 h of treatment (34). To test if InhA inactivation
followed similar death kinetics as that seen in INH-treated
cells, we compared INH treatment of M. smegmatis to InhA
thermal inactivation in minimal medium. In both cases, we
observed an increase in the number of CFU during the first
hour, followed by up to 66% decrease after 3 h of treatment.
The viability continued to decrease up to 3 orders of magni-
tude after 7 h for wt M. smegmatis mc2155 treated with INH
and for each of the mutants after thermal inactivation (Fig. 5A
to C). Faster death kinetics were observed when the cells were
incubated in Mueller-Hinton medium compared to 7H9 min-
imal medium (Fig. 5B and C). Notably, the cultures reproduc-
ibly displayed significant lysis 9 h postinduction in both media
(Fig. 5D).
To visualize the events leading to lysis, scanning electron
microscopy was performed on representative cells at various
times after thermal inactivation or INH treatment (Fig. 6). At
initial times, cells appeared normal with a smooth and long
shape, with dimensions of 0.5 mm in diameter and 3 to 5 mm in
length. At 3 h post-InhA inactivation or -INH treatment, the
cells began to form blebs at sporadic sites across the cell sur-
face. With increasing time, the blebs appeared to turn into
filaments and eventually shred from the cell wall surface. Con-
comitant with the massive shredding, the cells appeared to
shorten in length, widen in cell diameter, and undergo lysis.
DISCUSSION
Direct selection for thermosensitive mutations in genes en-
coding drug targets. Ts mutants represent powerful tools to
identify genes encoding essential functions and to study met-
abolic pathways. In our case, we wished to isolate a Ts allele
specifically in inhA, a gene encoding the enoyl-ACP reductase
of the FASII system of mycobacteria. Typically, libraries of
mutagenized cells are screened for mutants that fail to grow at
nonpermissive temperatures and then the resulting mutants
are genetically characterized to identify the mutated gene. This
approach has been successfully used for M. smegmatis to iden-
tify a number of essential genes, but the screening of 200,000
mutagenized population of mutants thus far has failed to yield
a Ts allele in inhA (3, 17). Since INH-R could be mediated by
mutations in the inhA gene (1), we reasoned that Ts alleles of
inhA could be identified from a large set of spontaneous
INH-R mutants isolated at 30°C, as an amino acid substitution
conferring INH-R might also confer thermosensitivity to the
InhA enzyme. Skold had successfully used a similar strategy to
isolate Ts alleles in the gene encoding dihydropteroate syn-
thase, the target of sulfonamides (32). Since we had previously
shown that the mutations conferring resistance to INH that are
Ts map to ndh, a gene encoding an NADH dehydrogenase
(25), we reasoned ndh(Ts) alleles could be eliminated from our
screen by starting with a strain that was merodiploid for ndh.
Using this approach, spontaneous INH-R mutants were iso-
lated at frequencies of 4 3 1027 to 4 3 1026. Approximately
14% of the INH-R mutants were Ts for growth, and 2% were
found to map to inhA. Based on our success and that of Skold,
FIG. 4. INH treatment or InhA inactivation causes accumulation of C24:0. The bars represent the percentage of C16:0 and C24:0 for the M. smegmatis strains and
C16:0 and C26:0 for the BCG strain, obtained from the corresponding signals in the HPLC radiochromatograms. INH50 and INH1, INH at 50 and 1 mg/ml, respectively.
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we would suggest that this approach could be generally applied
to isolate Ts alleles of any gene encoding a drug target.
Inactivation of the FASII enoyl-reductase inhibits mycolic
acid biosynthesis and induces cell lysis. The two independent
inhA(Ts) mutants isolated are identical mutants, both having a
single point mutation in inhA (V238F) which confers resistance
to INH and ETH and renders the InhA enzyme inactive at
42°C. This V238F substitution occurs in the NADH binding
pocket of the InhA protein, like other alleles conferring
INH-R and ETH-R, and likely reduces the binding of the
INH-NAD adduct to mediate the resistance. Our inability to
isolate extragenic suppressors establishes that InhA has no
redundant function in M. smegmatis. The selective inhibition of
InhA in M. smegmatis upon thermal inactivation results in an
inhibition of mycolic acid biosynthesis and accumulation of the
long-chain saturated fatty acid C24:0. The inhibition of mycolic
acid biosynthesis confirms that the FASII pathway, which InhA
is part of, is primarily responsible for the elongation of fatty
acids to mycolic acids in vivo. The saturated fatty acids that
accumulate following InhA inactivation and FASII inactivation
leads us to conclude that these fatty acids emanate from FASI
since these are the same products observed for FASI activity in
vitro (27). Most importantly, InhA inactivation induces the
lysis of M. smegmatis cells. The death kinetics of M. smegmatis
cells following InhA inactivation are very similar to those seen
in M. smegmatis cells treated with INH. In both cases, a com-
mon series of cell surface blebbing followed by shredding pre-
ceded the cell lysis. These morphological changes are strikingly
similar to those reported for M. tuberculosis treated with INH
(35).
Is InhA the primary target of INH in M. tuberculosis? M.
tuberculosis is 100-fold more sensitive to INH than M. smeg-
matis is. To explain this difference, Mdluli et al. have postu-
lated that M. tuberculosis has a different target for INH than M.
smegmatis (22). They argue that InhA can not be the target as
the inhibition of inhA-encoded enoyl reductase could not ac-
count for the accumulation of C26:0 observed following treat-
ment of M. tuberculosis with INH (22). However, since this
present work demonstrates that InhA inactivation leads to the
accumulation of FASI end products and in vitro studies have
established that FASI of M. bovis BCG synthesizes C26:0 (16),
we believe it is reasonable to extrapolate that InhA inactivation
in M. tuberculosis would also lead to an accumulation of C26:0.
Mdluli et al. have also provided evidence for another target by
demonstrating that radioactive INH covalently attaches to
AcpM, the ACP of FASII, in a complex with the kasA-encoded
b-keto acyl synthase in M. tuberculosis (23). While this estab-
lishes binding, this is but one criterion for a target. A drug
target for a bactericidal drug is an enzyme of the bacterium (i)
that binds the drug, (ii) that is inhibited by the drug, and (iii)
whose inhibition induces the death of the bacterium. All three
criteria have been demonstrated for InhA. INH is a prodrug
which, when activated by the catalase-peroxidase katG (Fig.
1B), attacks NAD, and the resulting INH-NAD adduct is the
actual drug which binds the InhA enzyme (20, 31, 38) and
inhibits InhA function (2, 15, 41). In this study, we demonstrate
the third criterion by showing that the inactivation of InhA is
alone sufficient to induce the lysis of M. smegmatis in a manner
similar to INH action. While a similar study needs to be per-
formed for M. tuberculosis, analysis of mutations in clinical
isolates of INH-R strains suggests that this will hold true. First,
mutations have been identified within the structural inhA gene
from M. tuberculosis and their resulting altered enzymes have
been shown to be resistant to KatG-activated INH (2, 10, 30).
Moreover, two different mutations that map to the expression
region of the mabA-inhA operon of M. tuberculosis have been
found in as many as 30% of INH-R isolates and consistently
correlate with resistance to INH and ETH (14, 37). Such ex-
pression-enhancing mutations would increase InhA levels in-
side a cell, and overexpressed InhA genes from M. tuberculosis,
M. bovis, and M. smegmatis all confer INH-R and ETH-R to M.
smegmatis cells and INH-R to inhibition of cell extracts (1). In
contrast, no evidence has yet been reported that M. tuberculosis
KasA activity is inhibited by activated INH nor that mutant
KasA proteins are resistant to inhibition. Genetic evidence has
not consistently supported the argument that kasA is a target.
Initially four mutations in the kasA gene were found to corre-
late with INH-R, but two independent reports have demon-
strated that two of these mutations are found in INH-S strains
of M. tuberculosis (19, 28). Moreover, while kasA and kasB
have been shown to confer resistance to thiolactomycin when
cloned on multicopy expression vectors in BCG, no resistance
to INH was observed (18). While our results suggest that in-
hibition of any of the enzymes of the FASII pathway might
lead to lysis, it will be necessary to demonstrate that KasA
activity is not duplicated by the highly homologous KasB pro-
tein. Even if binding and inhibition are established for KasA,
like InhA, the primary target would likely represent the rate-
limiting step for the FASII pathway. For E. coli, this rate-
limiting step has been shown to be the enoyl-reductase (13). It
appears to be the same for the FASII system of M. tuberculosis
as kasA has been shown to be induced following INH treat-
ment, while inhA expression is not (23, 39). Thus, if KasA is not
FIG. 5. Viability of M. smegmatis following INH treatment or InhA inacti-
vation. The strains were grown at 30°C up to an early log phase (OD ’ 0.2), INH
(25 mg/ml) was added to wt mc2155, and then all the cultures were shifted to
42°C. Samples were taken every 60 to 90 min, diluted, and plated in duplicate on
Mueller-Hinton plates. The plates were incubated at 30°C for 6 days, and the
CFU were then counted. The mean CFU per milliliter from four independent
experiments for InhA inactivation are shown: wt M. smegmatis following incu-
bation with 25 mg/ml INH (A), mc22359 (Ts mutant) (B), and mc22360 (Ts
mutant) (C). (D) Cell lysis of M. smegmatis in Mueller-Hinton broth following
thermal inactivation of InhA. Left, wt M. smegmatis incubated at 42°C for 9 h;
right, mc22359 incubated at 42°C for 9 h.
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the rate-limiting step, an alternative explanation for INH-R, if
it is mediated by the KasA-AcpM binding of INH, might be
that the KasA-ACP complex titrates the activated INH species
to prevent inhibition of the rate-limiting InhA activity. Such a
role would be secondary to InhA.
In contrast to M. smegmatis having a different target for INH
compared to M. tuberculosis, we propose that the 100-fold-
increased sensitivity for INH in M. tuberculosis compared to M.
smegmatis results from an increased ability to generate the
InhA inhibitor, the INH-NAD adduct. Two different mecha-
nisms could be proposed to prevent formation of the adduct
leading to INH-R: (i) the loss of the activator KatG (42) or (ii)
increased NADH/NAD ratios (25, 38). Definitive elucidation
of the roles that inhA and kasA play in INH-R will require the
construction of isogenic strains of M. tuberculosis differing by
single point mutations and subsequent product analysis. Al-
though this has been unachievable to date for technical rea-
sons, we have developed a novel specialized transduction sys-
tem which should enable allelic exchanges involving the
transfer of specific point mutations linked to a selectable
marker gene (12; S. Bardarov et al., unpublished data).
FASII enzymes represent attractive drug targets for myco-
bacteria. Ultimately, the knowledge that InhA inactivation in-
duces the lysis of mycobacteria underscores the importance of
the InhA enzyme for further drug development to kill patho-
genic mycobacteria, including INH-R variants of M. tuberculo-
sis. For example, it should be possible to design compounds
that require no activation step to inhibit InhA activity. More-
over, the availability of the inhA(Ts) mutant, the first fully
characterized Ts mutant in the FASII system of mycobacteria,
provides a system that should lead to a better understanding of
the events leading to the death of a mycobacterial cell. A better
understanding of the mechanism(s) underlying cell death of
INH-treated mycobacteria should allow the design of not only
improved enoyl-ACP reductase inhibitors but also drugs that
synergize to augment the mycobacterial killing process. In-
deed, all the FASII enzymes might represent attractive targets
for development of novel antimycobacterial agents.
FIG. 6. SEM of inhA(Ts) mutant of M. smegmatis mc22359. Shown are mc22359 at 0 h (A), 3 h (C), 6 h (E), and 9 h (F) and INH-treated wt M. smegmatis at 0 h
(B), 3 h (D), 6 h (F), and 9 h (H) after the temperature shift. Several fields were examined at each time point, and representative samples are shown in each panel.
The bar represents 1.0 mm.
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